Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
Anticancer Res. 2020 Apr;40(4):2291-2296. doi: 10.21873/anticanres.14194.
BACKGROUND/AIM: The best sequential treatment for castration-resistant prostate cancer (CRPC) remains unclear. This study evaluated the therapeutic effects of ethinylestradiol (EE) on CRPC.
A total of 80 patients with CRPC, treated with 0.5-1.5 mg/day of EE, were retrospectively assessed.
The median duration from the initial treatment to the beginning of EE was 48.3 months. A decline in the prostate-specific antigen (PSA) from the baseline was noted in 60 patients (75%) and a >50% PSA decline in 27 patients (34%). The median time of PSA progression, overall survival, and cancer-specific survival after EE were 5.60 months, 24.00 months, and 27.93 months, respectively.
EE administration for CRPC showed a relatively high PSA response regardless of timing of sequential treatment. The frequency of cardiovascular adverse events was not significantly high. EE administration is a potential treatment option for CRPC.
背景/目的：去势抵抗性前列腺癌（CRPC）的最佳序贯治疗仍不清楚。本研究评估了雌二醇（EE）对 CRPC 的治疗效果。
回顾性评估了 80 例接受 0.5-1.5 毫克/天 EE 治疗的 CRPC 患者。
从初始治疗开始到开始 EE 的中位时间为 48.3 个月。60 例患者（75%）的前列腺特异性抗原（PSA）从基线下降，27 例患者（34%）的 PSA 下降>50%。EE 后 PSA 进展、总生存和癌症特异性生存的中位时间分别为 5.60 个月、24.00 个月和 27.93 个月。
EE 治疗 CRPC 显示出相对较高的 PSA 反应，无论序贯治疗的时间如何。心血管不良事件的频率并不高。EE 治疗是 CRPC 的一种潜在治疗选择。
